Jasper Therapeutics, Inc. (JSPR)
Nasdaq · Healthcare · Biotechnology
$0.5928+4.88%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $19.7M
- 52-week range
- $0.315 – $2.69
- 52-week change
- −76.75%
- EPS (trailing)
- −$1.04
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 10, 2026
Fiscal year to Dec 2025
- Net income
- −$0K
- Diluted EPS
- −$3.95
From the company’s annual report on SEC EDGAR.
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is based in Redwood City, California.
Headquarters: Redwood City, United States · jaspertx.com